Related Experiment Videos
Hematology and pathology devices; reclassification; restricted devices; OTC test sample collection systems for drugs
Insights
The Food and Drug Administration (FDA) proposes reclassifying over-the-counter (OTC) drug abuse test sample collection systems to Class I, exempting them from premarket review and manufacturing rules. These systems will be designated as restricted devices to ensure accuracy and reliability.
Area of Science:
- Regulatory Science
- Medical Device Classification
- Public Health
Background:
- Over-the-counter (OTC) test sample collection systems for drugs of abuse testing are currently classified as Class III devices requiring premarket approval.
- This classification imposes significant regulatory burdens, potentially limiting access and innovation.
Purpose of the Study:
- To propose reclassifying OTC test sample collection systems for drugs of abuse testing from Class III to Class I.
- To exempt these systems from premarket notification (510(k)) and current good manufacturing practice (CGMP) requirements.
- To designate these systems as restricted devices to ensure accuracy, reliability, laboratory competency, and adequate consumer communication.
Main Methods:
- Proposed regulatory action by the Food and Drug Administration (FDA).
- Analysis of existing device classifications and regulatory requirements.
- Development of proposed restrictions to ensure device safety and effectiveness.
Main Results:
- Reclassification of OTC drug abuse test sample collection systems from Class III to Class I.
- Exemption from premarket notification (510(k)) and CGMP requirements.
- Designation as restricted devices with specific consumer protection requirements.
Conclusions:
- The proposed changes aim to streamline regulation while maintaining consumer safety for OTC drug abuse testing.
- Restricted device designation will ensure accuracy, laboratory competence, and clear communication of results.
- Conforming amendments will clarify the scope of existing regulations for specimen transport containers.
Abstract:
The Food and Drug Administration (FDA) is proposing to reclassify over-the-counter (OTC) test sample collection systems for drugs of abuse testing from class III (premarket approval) into class I (general controls), and to exempt them from the premarket notification (510(k)) and current good manufacturing practice (CGMP) requirements. FDA is also proposing to designate OTC test sample collection systems for drugs of abuse testing as restricted devices under the Federal Food, Drug, and Cosmetic Act (the act), and to establish restrictions intended to assure consumers that: The underlying laboratory test(s) are accurate and reliable; the laboratory performing the test(s) has adequate expertise and competency; and the product has adequate labeling and methods of communicating test results to consumers. Finally, FDA is proposing a conforming amendment to the existing classification regulation for specimen transport and storage containers, to clarify that it does not apply to specimen transport and storage containers that are part of an OTC test sample collection system for the purpose of testing for the presence of drugs of abuse or their metabolites in a laboratory.